Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 7Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Platinum-resistant Ovarian Cancer 1Locally Advanced Non-small Cell Lung Cancer 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × anlotinib × Clear all
NCT04947371 2021-07-01

Adjuvant Therapy With Anlotinib for HCC

Shanghai Zhongshan Hospital

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡